CO6660423A2 - Composiciones y métodos para tratar la enfermedad de gaucher - Google Patents
Composiciones y métodos para tratar la enfermedad de gaucherInfo
- Publication number
- CO6660423A2 CO6660423A2 CO12036036A CO12036036A CO6660423A2 CO 6660423 A2 CO6660423 A2 CO 6660423A2 CO 12036036 A CO12036036 A CO 12036036A CO 12036036 A CO12036036 A CO 12036036A CO 6660423 A2 CO6660423 A2 CO 6660423A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- disease
- compositions
- gaucher
- gaucher disease
- Prior art date
Links
- 208000015872 Gaucher disease Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000004547 Glucosylceramidase Human genes 0.000 abstract 1
- 108010017544 Glucosylceramidase Proteins 0.000 abstract 1
- 238000002641 enzyme replacement therapy Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2442—Chitinase (3.2.1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01014—Chitinase (3.2.1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
Abstract
La invención se relaciona con composiciones y métodos para seleccionar un tratamiento para un sujeto con enfermedad de Gaucher, seleccionar sujetos para el tratamiento con la terapia de reemplazo de enzima glucocerebrosidasa, métodos para reducir la reacción en él sitio de inyección en sujetos sometidos a tratamiento para la enfermedad de Gaucher, y métodos para tratar la enfermedad de Gaucher. La presente invención también se relaciona cori métodos para determinar la producción de anticuerpos, por ejemplo, producción de anticuerpos neutralizantes, en un sujeto que está siendo tratado por la enfermedad de Gaucher.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22919509P | 2009-07-28 | 2009-07-28 | |
US30304410P | 2010-02-10 | 2010-02-10 | |
US31751310P | 2010-03-25 | 2010-03-25 | |
US33337210P | 2010-05-11 | 2010-05-11 | |
US35933810P | 2010-06-28 | 2010-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6660423A2 true CO6660423A2 (es) | 2013-04-30 |
Family
ID=43527246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12036036A CO6660423A2 (es) | 2009-07-28 | 2012-03-01 | Composiciones y métodos para tratar la enfermedad de gaucher |
Country Status (16)
Country | Link |
---|---|
US (2) | US20110027254A1 (es) |
EP (2) | EP2459212B1 (es) |
JP (5) | JP5815521B2 (es) |
CN (3) | CN102686237B (es) |
AU (3) | AU2010281403B2 (es) |
CA (2) | CA2768999C (es) |
CO (1) | CO6660423A2 (es) |
ES (2) | ES2887552T3 (es) |
HK (2) | HK1258919A1 (es) |
IL (3) | IL262668B1 (es) |
MX (2) | MX2012001268A (es) |
NZ (3) | NZ713967A (es) |
PL (1) | PL3354277T3 (es) |
RU (2) | RU2733466C2 (es) |
WO (1) | WO2011017177A1 (es) |
ZA (2) | ZA201200704B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
AU2007212021B2 (en) | 2006-02-07 | 2013-06-06 | Takeda Pharmaceutical Company Limited | Stabilized compositions of proteins having a free thiol moiety |
WO2009155936A1 (en) | 2008-06-26 | 2009-12-30 | Orphazyme Aps | Use of hsp70 as a regulator of enzymatic activity |
MX2012001268A (es) | 2009-07-28 | 2012-09-12 | Shire Human Genetic Therapies | Composiciones y metodos para tratar enfermedad de gaucher. |
EP2595651B1 (en) * | 2010-07-19 | 2017-03-29 | Shire Human Genetic Therapies, Inc. | Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof |
JP2013544263A (ja) | 2010-11-30 | 2013-12-12 | オルファザイム エーピーエス | Hsp70の細胞内活性を上昇させる方法 |
US9387236B2 (en) * | 2011-06-10 | 2016-07-12 | Prothera Inc. | Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases |
HUE037811T2 (hu) | 2011-10-28 | 2018-09-28 | Prothena Biosciences Ltd | Alfa-szinukleint felismerõ humanizált antitestek |
WO2013112945A1 (en) | 2012-01-27 | 2013-08-01 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
US9623090B2 (en) * | 2012-03-02 | 2017-04-18 | Shire Human Genetic Therapies, Inc. | Compositions and methods for treating type III gaucher disease |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
HUE054957T2 (hu) | 2014-09-15 | 2021-10-28 | Orphazyme As | Arimoklomol készítése |
WO2017053605A1 (en) * | 2015-09-22 | 2017-03-30 | Saint Louis University | Iminosugars for improving bone mineral density in bone disease |
US10898476B2 (en) | 2016-04-13 | 2021-01-26 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
HUE052158T2 (hu) | 2016-04-29 | 2021-04-28 | Orphazyme As | Arimoklomol a glükocerebroszidázzal társult rendellenességek kezeléséhez |
EP3264092A1 (en) * | 2016-07-01 | 2018-01-03 | Centogene AG | Use of lyso-gb1 as druggable target |
EP3700526A4 (en) * | 2017-10-26 | 2021-09-08 | Takeda Pharmaceutical Company Limited | FORMULATIONS CONTAINING GLUCOCEREBROSIDASE AND ISOFAGOMINE |
WO2019231725A2 (en) * | 2018-05-27 | 2019-12-05 | Bioasis Technolgies Inc. | Treatment of gaucher disease |
CN113906012A (zh) * | 2019-04-25 | 2022-01-07 | 武田药品工业有限公司 | 异法戈明盐、使用方法和调配物 |
US11891588B2 (en) | 2019-07-31 | 2024-02-06 | Ecolab Usa Inc. | Personal protective equipment free delimer compositions o |
RU2759054C2 (ru) * | 2019-11-27 | 2021-11-09 | федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) | Рекомбинантный штамм вируса гриппа A/PR8-NS124-Luc и способ оценки поствакцинальных нейтрализующих антител с использованием биолюминесцентной детекции |
WO2021213422A1 (en) * | 2020-04-23 | 2021-10-28 | Wuxi Biologics (Shanghai) Co., Ltd. | A genetically modified cell line producing a recombinant glycoprotein having a mannose-terminated n-glycan |
JP2023531750A (ja) * | 2020-06-24 | 2023-07-25 | ケムファーム デンマーク アー/エス | ゴーシェ病を処置するためのアリモクロモル |
JP2023544735A (ja) * | 2020-10-01 | 2023-10-25 | サンガモ セラピューティクス, インコーポレイテッド | 抗aav抗体を検出する方法 |
KR20230128462A (ko) | 2020-11-19 | 2023-09-05 | 제브라 덴마크 에이/에스 | 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5241093B2 (es) | 1973-05-16 | 1977-10-17 | ||
US5272066A (en) * | 1986-03-07 | 1993-12-21 | Massachusetts Institute Of Technology | Synthetic method for enhancing glycoprotein stability |
US4925796A (en) * | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
AU2946289A (en) | 1987-12-23 | 1989-07-19 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Cloned dna for synthesizing unique glucocerebrosidase |
JPH03503721A (ja) | 1988-12-23 | 1991-08-22 | ジェンザイム コーポレイション | 酵素的に活性な組換えグルコセレブロシダーゼ |
DE68926569T2 (de) | 1988-12-23 | 1996-09-26 | Genzyme Corp | Cho-zellen befähigt enzymatisch aktive rekombinante-glukocerebrosidase zu produzieren |
US5236838A (en) * | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
US5549892A (en) * | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
DE69213714T2 (de) | 1991-01-21 | 1997-01-23 | Genzyme Corp | Herstellung enzymatischer aktiver glukocerebrosidase von rekombinanten zellen |
EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US6270989B1 (en) * | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
US5911983A (en) | 1992-06-26 | 1999-06-15 | University Of Pittsburgh | Gene therapy for Gaucher disease using retroviral vectors |
DE69331805T2 (de) | 1992-12-10 | 2002-11-28 | Enzon Inc | Glycolipid enzym-polymer konjugate |
WO1994014837A1 (en) | 1992-12-21 | 1994-07-07 | Enzon, Inc. | Purification of proteinaceous material |
DE69521074T2 (de) | 1994-03-30 | 2001-09-13 | Takara Shuzo Co | Transglykosylierungsverfahren zur Herstellung eines Kohlenhydrats oder eines Glykokonjugates |
JP3002113B2 (ja) | 1994-03-30 | 2000-01-24 | 寳酒造株式会社 | 糖質又は複合糖質の製造方法 |
US5670132A (en) | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
EP1516628B1 (en) | 1995-07-27 | 2013-08-21 | Genentech, Inc. | Stable isotonic lyophilized protein formulation |
ES2326705T3 (es) | 1995-09-14 | 2009-10-16 | Virginia Tech Intellectual Properties, Inc. | Produccion de enzimas lisosomicas en sistemas de expresion basados en plantas. |
CN1149088C (zh) | 1996-03-05 | 2004-05-12 | 奥奎斯特公司 | 骨生长促进组合物及其用途 |
JP4564108B2 (ja) | 1996-07-15 | 2010-10-20 | ジェンザイム コーポレーション | デオキシノジリマイシン誘導体及び該誘導体のグルコシルセラミダーゼ阻害剤としての用途 |
WO1998011206A2 (en) | 1996-09-13 | 1998-03-19 | Transkaryotic Therapies, Inc. | THERAPY FOR α-GALACTOSIDASE A DEFICIENCY |
IL155588A0 (en) | 2003-04-27 | 2003-11-23 | Metabogal Ltd | Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
JPH10273500A (ja) | 1997-03-03 | 1998-10-13 | Noguchi Inst | 複合糖ペプチド及びその製造法 |
JPH10306099A (ja) | 1997-03-04 | 1998-11-17 | Noguchi Inst | 新規複合糖ペプチドおよびその製法 |
TW542721B (en) | 1997-08-06 | 2003-07-21 | Melaleuca Inc | Dietary supplements containing natural ingredients |
CA2299271C (en) | 1997-08-07 | 2009-02-03 | University Of Utah | Prodrugs and conjugates of thiol- and selenol- containing compounds and methods of use thereof |
US5939279A (en) * | 1997-09-18 | 1999-08-17 | The Board Of Trustees Of The University Of Arkansas | Inhibition of bacterial binding by high-mannose oligosaccharides |
CA2316015A1 (en) | 1997-12-22 | 1999-07-01 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
GB9802249D0 (en) | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
GB9807464D0 (en) | 1998-04-07 | 1998-06-10 | Pharming Bv | Purification of human acid µ-glucosidase |
EP0976838A1 (en) | 1998-05-06 | 2000-02-02 | Rhone-Poulenc Nutrition Animale | Enzymes mixture |
JPH11318441A (ja) | 1998-05-14 | 1999-11-24 | Nagase & Co Ltd | 超耐熱耐酸性アミロプルラナーゼ |
KR19990086271A (ko) | 1998-05-27 | 1999-12-15 | 손경식 | 면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제 |
IL139739A0 (en) | 1998-06-05 | 2002-02-10 | Aventis Pharma Sa | Polypeptides with beta-secretase type activity |
ES2558160T3 (es) | 1998-12-09 | 2016-02-02 | Phyton Holdings, Llc | Glicoproteínas que tienen glicosilación de tipo humano |
GB9909066D0 (en) * | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
WO2000076480A2 (en) * | 1999-06-11 | 2000-12-21 | Eli Lilly And Company | Pharmaceutical materials and methods for their preparation and use |
AU6050600A (en) | 1999-07-26 | 2001-02-13 | G.D. Searle & Co. | Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidaseenzyme for the manufacture of medicament for the treatment of glycolipid storag e diseases |
US6642038B1 (en) * | 1999-09-14 | 2003-11-04 | Genzyme Glycobiology Research Institute, Inc. | GlcNAc phosphotransferase of the lysosomal targeting pathway |
US6770468B1 (en) * | 1999-09-14 | 2004-08-03 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway |
CA2477857C (en) | 1999-10-04 | 2012-04-10 | Chiron Corporation | Stabilized liquid polypeptide-containing pharmaceutical compositions |
IL150314A0 (en) | 1999-12-30 | 2002-12-01 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
US20040204379A1 (en) * | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US20020095135A1 (en) * | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
CN1156702C (zh) * | 2001-07-11 | 2004-07-07 | 上海晶泰生物技术有限公司 | 采用标记链霉亲和素-生物素技术的蛋白质芯片 |
JP4249028B2 (ja) | 2001-12-04 | 2009-04-02 | 田辺三菱製薬株式会社 | 蛋白質の活性化方法 |
KR20040085185A (ko) | 2002-02-14 | 2004-10-07 | 추가이 세이야쿠 가부시키가이샤 | 항체함유 용액제제 |
US7429460B2 (en) * | 2003-01-15 | 2008-09-30 | Yeda Research And Development Co., Ltd. | Methods of screening for inhibitors of phospholipid synthesis related to glycolipid-storage diseases |
US20040202666A1 (en) | 2003-01-24 | 2004-10-14 | Immunomedics, Inc. | Anti-cancer anthracycline drug-antibody conjugates |
CA2814774C (en) | 2003-01-31 | 2016-03-22 | Mount Sinai School Of Medicine Of New York University | Combination therapy for treating protein deficiency disorders |
US7951557B2 (en) | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
WO2005108989A2 (en) * | 2004-04-16 | 2005-11-17 | Genentech, Inc. | Assay for antibodies |
US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
DK2399893T3 (en) | 2004-12-22 | 2018-10-08 | Ambrx Inc | COMPOSITIONS CONTAINING, INVOLVING PROCEDURES, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES |
NZ599176A (en) | 2005-08-03 | 2014-04-30 | Immunogen Inc | Immunoconjugate formulations |
AU2007212021B2 (en) | 2006-02-07 | 2013-06-06 | Takeda Pharmaceutical Company Limited | Stabilized compositions of proteins having a free thiol moiety |
ES2366059T3 (es) * | 2006-03-17 | 2011-10-14 | Biomarin Pharmaceutical Inc. | Ensayos para la detección de anticuerpos anti-enzimas lisosómicas. |
KR20090040258A (ko) * | 2006-04-18 | 2009-04-23 | 이케이알 테라퓨틱스, 인코포레이티드 | 사전혼합된, 즉석용 약제 조성물 |
ATE504570T1 (de) | 2006-05-24 | 2011-04-15 | Amicus Therapeutics Inc | Tartratsalz aus isofagomin und verwendungsverfahren dafür |
CA2656643C (en) * | 2006-06-23 | 2015-08-25 | Amicus Therapeutics, Inc. | Method for the treatment of neurological disorders by enhancing the activity of .beta.-glucocerebrosidase |
SI2495307T1 (en) * | 2006-07-13 | 2018-05-31 | Wyeth Llc | Production of the calibration factor IX with an improved glycolization pattern |
TWI489984B (zh) * | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
MX2012001268A (es) | 2009-07-28 | 2012-09-12 | Shire Human Genetic Therapies | Composiciones y metodos para tratar enfermedad de gaucher. |
EP2542572B1 (en) | 2010-03-02 | 2015-05-06 | Protalix Ltd. | Multimeric forms of therapeutic proteins and uses thereof |
EP2595651B1 (en) | 2010-07-19 | 2017-03-29 | Shire Human Genetic Therapies, Inc. | Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof |
-
2010
- 2010-07-28 MX MX2012001268A patent/MX2012001268A/es active IP Right Grant
- 2010-07-28 PL PL18161509T patent/PL3354277T3/pl unknown
- 2010-07-28 MX MX2015000528A patent/MX344786B/es unknown
- 2010-07-28 NZ NZ713967A patent/NZ713967A/en unknown
- 2010-07-28 CA CA2768999A patent/CA2768999C/en active Active
- 2010-07-28 ES ES18161509T patent/ES2887552T3/es active Active
- 2010-07-28 CA CA3120503A patent/CA3120503A1/en not_active Abandoned
- 2010-07-28 NZ NZ623910A patent/NZ623910A/en active IP Right Revival
- 2010-07-28 WO PCT/US2010/043586 patent/WO2011017177A1/en active Application Filing
- 2010-07-28 JP JP2012523006A patent/JP5815521B2/ja active Active
- 2010-07-28 CN CN201080042877.7A patent/CN102686237B/zh active Active
- 2010-07-28 US US12/845,653 patent/US20110027254A1/en not_active Abandoned
- 2010-07-28 IL IL262668A patent/IL262668B1/en unknown
- 2010-07-28 CN CN201510580649.XA patent/CN105126086B/zh active Active
- 2010-07-28 EP EP10806936.0A patent/EP2459212B1/en active Active
- 2010-07-28 RU RU2015141669A patent/RU2733466C2/ru active
- 2010-07-28 EP EP18161509.7A patent/EP3354277B1/en active Active
- 2010-07-28 AU AU2010281403A patent/AU2010281403B2/en active Active
- 2010-07-28 NZ NZ598156A patent/NZ598156A/en not_active Application Discontinuation
- 2010-07-28 RU RU2012107103/15A patent/RU2568831C2/ru active
- 2010-07-28 CN CN201811078247.XA patent/CN109172813B/zh active Active
- 2010-07-28 ES ES10806936.0T patent/ES2668079T3/es active Active
-
2012
- 2012-01-26 IL IL217774A patent/IL217774B/en active IP Right Grant
- 2012-01-27 ZA ZA2012/00704A patent/ZA201200704B/en unknown
- 2012-03-01 CO CO12036036A patent/CO6660423A2/es unknown
- 2012-11-20 HK HK19101396.7A patent/HK1258919A1/zh unknown
-
2014
- 2014-01-31 US US14/169,628 patent/US11571466B2/en active Active
-
2015
- 2015-03-09 JP JP2015045704A patent/JP6066503B2/ja active Active
- 2015-07-31 ZA ZA2015/05556A patent/ZA201505556B/en unknown
-
2016
- 2016-02-05 AU AU2016200739A patent/AU2016200739B2/en active Active
- 2016-05-16 HK HK16105586.1A patent/HK1217449A1/zh unknown
- 2016-07-11 JP JP2016136753A patent/JP6378257B2/ja active Active
-
2018
- 2018-01-04 JP JP2018000259A patent/JP2018077246A/ja active Pending
- 2018-05-11 AU AU2018203308A patent/AU2018203308B2/en active Active
- 2018-05-16 IL IL259413A patent/IL259413B/en active IP Right Grant
-
2019
- 2019-10-28 JP JP2019194895A patent/JP2020033367A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6660423A2 (es) | Composiciones y métodos para tratar la enfermedad de gaucher | |
CY1121065T1 (el) | Αναστολεις ιβατ για την αγωγη ηπατικων νοσων | |
MX2019005130A (es) | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente. | |
MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
BR112013023774A2 (pt) | inibidores de glicosilceramida sintase | |
BRPI1013705A2 (pt) | compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica | |
BR112012009123A2 (pt) | novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossômico | |
MX2010004074A (es) | Combinacion 059. | |
EP2381957A4 (en) | THERAPEUTIC MODULATION OF VAGINAL EPITHELIUM LIMITING LUBRICATION | |
MX2012000034A (es) | Metodos para el tratamiento o la prevencion de la fatiga. | |
EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
EA201000559A1 (ru) | Композиции и способы применения антител к склеростину | |
MX2012002449A (es) | Terapia de reemplazo de enzimas con aumento escalonado de la dosis para tratar la deficiencia de esfingomielinasa acida. | |
MX2022004300A (es) | Composicion y metodo para el diagnostico y tratamiento de enfermedades asociadas con la degeneracion de neuritas. | |
BR112012006283A2 (pt) | formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte | |
BR112013004700A2 (pt) | método para prevenir ou tratar doenças ou distúrbios cardiovasculares | |
WO2010097788A3 (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
BR112012009121A2 (pt) | Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central | |
BRPI0919944A2 (pt) | aparelho e método para tratamento ultrassônico da espinha | |
BR112014003071A2 (pt) | tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical | |
BR112012005837A8 (pt) | Composição de enzimas digestivas em multipartículas, forma de dosagem, método para o tratamento da dor proveniente da pancreatite, método para o tratamento da dor proveniente da pancreatite e da insuficiência pancreática, método para o tratamento da insuficiência pancreática exócrina e método para o tratamento da dor pancreática | |
BR112014000634A2 (pt) | métodos para tratamento de incontinência associada com atividade sexual | |
EA201200428A1 (ru) | Композиция и способ для лечения ожирения | |
ECSP088764A (es) | Métodos para tratar trastornos cognitivos y otros afines | |
BR112013000045A2 (pt) | derivados de aminoácido n-acil para o tratamento de condições cutâneas como celulite |